EGFR and hepatocellular carcinoma: Most notably, the combination of regorafenib with gefitinib inhibits proliferation and promotes apoptosis in regorafenib-resistant HCC cells, indicating that EGFR inhibition by gefitinib has the potential to overcome acquired resistance to regorafenib treatment.